[Clinical practice guideline for stage Ⅳ primary lung cancer in China(2021 version)].
[Clinical practice guideline for stage Ⅳ primary lung cancer in China(2021 version)].
复制标题
DOI：
10.3760/cma.j.cn112152-20201009-00884
复制
发表时间：
2021-01-23
期刊：
影响因子：
--
通讯作者：
中科院分区：
文献类型：
--
作者：
原发性肺癌是中国最常见的恶性肿瘤，也是癌症死亡的首要原因，2015年估计有78.7万病例和63.1万人死亡。由于肺癌的侵袭性和缺乏有效的早期筛查方法，中国肺癌患者确诊时大多处于Ⅳ期。化疗是Ⅳ期肺癌的基石，但其疗效并不理想。近年来，随着分子靶向治疗和免疫治疗的快速发展，治疗理念不断改变，患者的生存也得到了极大的提高。为及时更新全球Ⅳ期肺癌治疗进展，进一步提高中国Ⅳ期肺癌规范化诊疗水平，中国临床肿瘤学家协会、中国国际医疗卫生交流促进会肿瘤医学分会组织专家制定了《中国Ⅳ期原发性肺癌临床实践指南(2021年版)》。
Primary lung cancer is the most common malignancy and the leading cause of cancer death in China, with an estimated 787 thousands incident cases and 631 thousands deaths in 2015. Due to its aggressive behavior and the absence of effective early screening methods, most patients with lung cancer in China are in stage Ⅳ when diagnosed. Chemotherapy is the cornerstone of stage Ⅳ lung cancer, but its efficacy is unsatisfactory. In recent years, with the rapid development of molecular targeted therapy and immunotherapy, the treatment concept has continuously changed and survival for patients has also been greatly improved. In order to update the progress in the treatment of stage Ⅳ lung cancer worldwide timely, and further improve the level of standardized diagnosis and treatment of stage Ⅳ lung cancer in China, Chinese Association for Clinical Oncologists and Medical Oncology Branch of Chinese International Exchange and Promotion Association for Medical and Healthcare organized experts to formulate "Clinical Practice Guideline for Stage Ⅳ Primary Lung Cancer in China(2021 version)" .